Carol Suh

@carolysuh

Biotech Venture Capital at ARCH Venture Partners My tweets are my own.

San Francisco, CA
Vrijeme pridruživanja: listopad 2014.

Tweetovi

Blokirali ste korisnika/cu @carolysuh

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @carolysuh

  1. proslijedio/la je Tweet
    26. sij
    Poništi
  2. proslijedio/la je Tweet
    8. sij

    Opinion: We must develop medicines with patients as our primary concern. Doing so will best serve the interests of patients, their caregivers, and health care providers, as well as those of shareholders and society at large.

    Poništi
  3. 16. pro 2019.
    Poništi
  4. proslijedio/la je Tweet

    My Op Ed in today’s . HR3 will reduce risk taking in life science. We’ll still get new drugs, but investment will shift into established targets using proven platforms like small molecules; and away from highest risk endeavors like gene editing

    Poništi
  5. 10. pro 2019.

    Congrats to for expanding their leadership team with James Burns and Kathie Bishop! Onwards and upwards.

    Poništi
  6. 10. pro 2019.

    100% R&D is a team sport. We need early stage innovators as well as later stage partners who can help scale. The ecosystem doesn't work otherwise.

    Poništi
  7. proslijedio/la je Tweet
    10. pro 2019.

    Venturing A Perspective On The Drug Pricing Debate. I've been largely quiet on this topic, but couldn't any longer. First principles of investin and what it means for pricing. Observations on the US system. And a few suggestions for policy emphasis.

    Poništi
  8. proslijedio/la je Tweet
    21. stu 2019.

    How to kill biotech innovation. 1. Kill the capital markets with insane taxes and “Medicare for all” that will cause a depression. (Capital is ALREADY fleeing ). 2. Propose pricing policies targeting pharma with no carve-outs for curative new medicines. Patients lose.

    Poništi
  9. proslijedio/la je Tweet

    Online Circular ecDNA promotes accessible chromatin and high oncogene expression

    Poništi
  10. 20. stu 2019.

    Check out the story on the science behind ! Super cool new way of looking at cancer with new Nature paper out. Paul Mischel Vineet Bafna

    Poništi
  11. 18. stu 2019.

    Excited about Karuna! Addressing huge need with minimal side effects. Potentially game changing.

    Poništi
  12. 28. lis 2019.

    Thank you for writing about this. It’s a topic that doesn’t get addressed enough.

    Poništi
  13. 23. lis 2019.

    Check out our CEO ’s interview at BIO! Great overview of how we’re tackling ecDNA driven cancers.

    Poništi
  14. 26. ruj 2019.

    Check out our 's CEO 's "molecules of wisdom" on building great culture in a biotech! My favorite "molecule" is #9. What's yours? Any others?

    Poništi
  15. 19. ruj 2019.

    So thrilled to be launching today! We're developing novel therapies to tackle difficult-to-treat cancers driven by extrachromosomal DNA (ecDNA). $46M by ARCH , City Hill , Vertex Ventures , GT, Boxer, AVI

    Poništi
  16. proslijedio/la je Tweet
    3. ruj 2019.

    Congrats to Semma founders and investors. ARCH was lucky to be a participant with F-prime, MPM, and others. Hopefully, this accelerates the potential for diabetes cell therapy.

    Poništi
  17. 24. srp 2019.

    Great podcast featuring ARCH Venture Partner Paul Berns! EQ is often underappreciated but is just as important if not more important than intellect.

    Poništi
  18. 13. svi 2019.

    was such a transformative experience for me ('05-'07 alum). How cool to have as the keynote this year!

    Poništi
  19. proslijedio/la je Tweet

    We’re at the 2019 NEVY Awards where we were named a 2019 Patient Impact Award Winner!

    Poništi
  20. 8. svi 2019.
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·